Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational
GlobeNewswireApr 25 16:05 ET
Relay Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational
GlobeNewswireApr 11 16:05 ET
FATE, ALPN and RLAY Are Among After Hour Movers
Seeking AlphaApr 10 17:20 ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersRallybio (NASDAQ:RLYB) shares rose 31.9% to $2.15 during Wednesday's after-market session. The company's market cap stands at $81.2 million. Vera Therapeutics (NASDAQ:VERA) shares increased by
BenzingaApr 10 16:31 ET
Strong Buy Rating for Relay Therapeutics Amid Pipeline Progress and Strategic Direction
TipRanksMar 19 01:38 ET
11 Oversold Biotech Stocks To Buy Right Now
Yahoo FinanceMar 17 17:20 ET
Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?
Yahoo FinanceMar 13 09:55 ET
Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year
Seeking AlphaMar 10 13:08 ET
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Relay Therapeutics (RLAY) and Regeneron (REGN)
TipRanksFeb 27 00:30 ET
Relay Therapeutics to Participate in Three Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational
GlobeNewswireFeb 26 16:05 ET
Relay Therapeutics: Strong Buy on Improved Financials and Promising Future Milestones
TipRanksFeb 26 06:18 ET
Relay Therapeutics Full Year 2023 Earnings: Beats Expectations
Yahoo FinanceFeb 24 09:15 ET
Relay Therapeutics (RLAY) Gets a Hold From Barclays
TipRanksFeb 23 03:05 ET
Optimistic Buy Rating for Relay Therapeutics: Strong Financial Standing and Strategic Pipeline Focus
TipRanksFeb 22 18:35 ET
Express News | Relay Therapeutics Q4 2023 GAAP EPS $(0.67) Beats $(0.75) Estimate
Moomoo 24/7Feb 22 16:24 ET
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort & initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg Initiated RLY-2608 + fulvestrant + ribociclib triplet
GlobeNewswireFeb 22 16:05 ET
Relay Therapeutics 4Q Loss/Shr 67c >RLAY
Relay Therapeutics 4Q Loss/Shr 67c >RLAY
Dow JonesFeb 22 16:05 ET
Relay Therapeutics Price Target Raised to $30.00/Share From $25.00 by Stifel
Relay Therapeutics Price Target Raised to $30.00/Share From $25.00 by Stifel
Dow JonesFeb 22 14:17 ET
Relay Therapeutics Is Maintained at Buy by Stifel
Relay Therapeutics Is Maintained at Buy by Stifel
Dow JonesFeb 22 14:17 ET
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. • Bausch Health Companies (NYSE:BHC) is expected t
BenzingaFeb 22 05:27 ET
No Data
No Data